Bradley McGregor

“Science in Seconds” with Bradley McGregor – ASCO

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

In our latest “Science in Seconds,” Dr. Bradley McGregor discusses two findings from the phase 3 TALAPRO-2 trial highlighting final overall survival with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment: one for unselected patients with metastatic castration-resistant prostate cancer (mCRPC) and one for patients with homologous recombination repair (HRR)-deficient mCRPC.

Abstract 1 –Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

Abstract 2 –Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

Link to video.

American Society of Clinical Oncology ASCO Bradley McGregor cancer fight against cancer Global awareness Global fight against cancer mCRPC OncoDaily Oncology Science in Seconds TALAPRO-2 trial